Evidence map›Paper›PMID 30952941›Full record

Trial reportScientific reports2019

Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF

Tjark F Schwemer, Navina Deutscher, Nadine Diermann, Rainer Böger, Edzard Schwedhelm, Stefan Blankenberg, Felix W Friedrich

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tjark F SchwemerUniversity Heart Center Hamburg, Hamburg, Germany.
Navina DeutscherUniversity Heart Center Hamburg, Hamburg, Germany.
Nadine DiermannUniversity Heart Center Hamburg, Hamburg, Germany.
Rainer BögerInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Edzard SchwedhelmInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan BlankenbergDZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany.
Felix W FriedrichInstitute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. f.friedrich@uke.de.ORCID http://orcid.org/0000-0002-8400-9445
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of the present study was to assess whether 6-week ranolazine application on top of guideline-based treatment impacts on the arginine/NO pathway and urinary isoprostane 8-iso-PGF

Indexed as

AgedAged, 80 and overAngina, UnstableArginineBiomarkersCardiovascular AgentsDinoprostFemaleHomoarginineHumansMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaOxidative StressRanolazine8-epi-prostaglandin F2alphaArginineBiomarkersCardiovascular AgentsDinoprostHomoarginineRanolazine

Identifiers

PMID30952941
PMCPMC6450888
OpenAlexW2933100610

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.